Recently, a new approach to the treatment of benign prostatic hyperplasia was found in the United States, where it has been laid at the basis of therapy reducing of the tumor. Scientists of such companies as Merck, Sharp & Dohme – the oldest and most authoritative American pharmaceutical company – have created a new drug Proscar. Now – this is the pride of the company. People, taking Proscar (one tablet a day) start to notice some decrease in adenoma. Consequently, the pressure on the urethra weakens, the lumen of urethra crushes, is passable – and getting better urination.
The necessary Proscar dosage can pick up only the doctor. The recommended dose is 5mg 1 time/day with or without food. Perhaps, you will be able to notice rapid improvement, but it may be necessary, at least 6 months in order to be able to assess the effectiveness of the therapy.
For patients with different stages of renal insufficiency (creatinine clearance with a decrease to 9 ml / min) is not necessary in the individual selection of doses as pharmacokinetic studies did not reveal any changes in the distribution of Proscar in these patients.
For elderly patients, there is no need in the selection of doses, although pharmacokinetic studies indicate that the dose of Proscar should be reduced in patients older than 70 years.
In most cases, patients treated with Proscar for 6 months or more, must double the level of prostate-specific antigen compared with the level of this index in untreated patients. Patients as having or not having prostate cancer, may have a significant match the values of prostate-specific antigen. Thus, in men with BPH normal levels of prostate-specific antigen can’t exclude the presence of prostate cancer regardless of Proscar treatment.
In studies on human volunteers there has been not found significant clinic interaction of Proscar with propranolol, digoxin, glyburide, warfarin, theophylline and antipyrine.
Apparently, Proscar has no appreciable effect on the enzyme system cytochrome P450 and, therefore, does not affect the pharmacokinetic parameters of drugs metabolized by microsomal enzymes.
In clinical studies, Proscar is used in conjunction with ACE inhibitors, alpha blockers, beta-blockers, calcium channel blockers, nitrates, diuretics, blockers of histamine H2-receptor inhibitors MMC-KoA reductase, NSAIDs, quinolones and benzodiazepines – clinically significant negative reactions were not shown.
The necessary Proscar dosage can pick up only the doctor. The recommended dose is 5mg 1 time/day with or without food. Perhaps, you will be able to notice rapid improvement, but it may be necessary, at least 6 months in order to be able to assess the effectiveness of the therapy.
For patients with different stages of renal insufficiency (creatinine clearance with a decrease to 9 ml / min) is not necessary in the individual selection of doses as pharmacokinetic studies did not reveal any changes in the distribution of Proscar in these patients.
For elderly patients, there is no need in the selection of doses, although pharmacokinetic studies indicate that the dose of Proscar should be reduced in patients older than 70 years.
In most cases, patients treated with Proscar for 6 months or more, must double the level of prostate-specific antigen compared with the level of this index in untreated patients. Patients as having or not having prostate cancer, may have a significant match the values of prostate-specific antigen. Thus, in men with BPH normal levels of prostate-specific antigen can’t exclude the presence of prostate cancer regardless of Proscar treatment.
In studies on human volunteers there has been not found significant clinic interaction of Proscar with propranolol, digoxin, glyburide, warfarin, theophylline and antipyrine.
Apparently, Proscar has no appreciable effect on the enzyme system cytochrome P450 and, therefore, does not affect the pharmacokinetic parameters of drugs metabolized by microsomal enzymes.
In clinical studies, Proscar is used in conjunction with ACE inhibitors, alpha blockers, beta-blockers, calcium channel blockers, nitrates, diuretics, blockers of histamine H2-receptor inhibitors MMC-KoA reductase, NSAIDs, quinolones and benzodiazepines – clinically significant negative reactions were not shown.